首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Clinicopathologic Characteristics and Prognostic Factors in Patients with Operable HER-2 Overexpressing Breast Cancer
【24h】

Clinicopathologic Characteristics and Prognostic Factors in Patients with Operable HER-2 Overexpressing Breast Cancer

机译:可操作的HER-2过表达乳腺癌患者的临床病理特征和预后因素

获取原文
           

摘要

Objective: To study the relationship between clinical pathologic characteristics, treatment modalities andprognostic factors in HER-2 (Human Epidermal growth factor Receptor-2) overexpressed breast carcinoma.Materials and Methods: Major clinico-pathological factors including therapeutic modalities and survival statusof 371 breast cancer patients with HER2 over-expression, teated at Yantai Yuhuangding Hospital from March of2002 to December of 2010 were retrospectively studied, with special attention focused on survival-related factors.Results: The median age of the total 371 patients in this study was 48 years at time of diagnosis, among which,the leading pathological type was infiltrating ductal carcinoma (92.5%); 62.8% presented with a primary tomorlarger than 2 cm in diameter at diagnosis, 51.0% had axillary lymph node (ALN) metastases; ER (Estrogenreceptor) /PR (Progesterone receptor) double negative occured in 52.8% of cases, and PCNA (proliferation cellnuclear antigen) (+++) was found in 55.1%. HER-2 overexpressed patients were usually in advanced stage whenthe diagnosis was made (72.8% at stages ⅡA~ⅢC). The prognosis and survival were assessed in 259 patientswith complete follow-up data. 5-year DFS (disease-free survival) and OS (overall survival) rate was 68.0% and78.0% respectively. Univariate analysis revealed that age, tumor size, ALN metastases, LVSI (lymph-vascularspace involvement), PCNA status, hormonal therapy, chemotherapy cycles, and HER-2 overexpression, correlatedclosely with the prognosis. ALN metastases, LVSI, PCNA status and chemotherapy cycles were independentpredictors of survival. Conclusions: HER-2 overexpressed breast cancer has special clinical and pathologicalcharacteristics, with advanced clinical stages and high rate of ER/PR double negative. Lymph node metastases,LVSI, PCNA and chemotherapy cycles are independent predictors of prognosis.
机译:目的:探讨人表皮生长因子受体-2(HER-2)高表达乳腺癌的临床病理特征,治疗方式与预后因素之间的关系。材料与方法:371例乳腺癌的主要临床病理因素包括治疗方式和生存状态回顾性研究2002年3月至2010年12月在烟台市玉皇顶医院就诊的HER2高表达患者,特别关注生存相关因素。结果:此项研究中371名患者的中位年龄为48岁。诊断时间,其中主要病理类型为浸润性导管癌(92.5%);诊断为原发灶直径大于2 cm的占62.8%,有腋窝淋巴结转移的占51.0%。 ER(雌激素受体)/ PR(孕酮受体)双重阴性发生在52.8%的病例中,PCNA(增殖细胞核抗原)(+++)的发生率为55.1%。 HER-2过表达的患者通常在诊断时处于晚期(ⅡA〜ⅢC期为72.8%)。通过完整的随访资料评估了259例患者的预后和生存率。 5年DFS(无病生存)和OS(总生存)率分别为68.0%和78.0%。单因素分析显示,年龄,肿瘤大小,ALN转移,LVSI(淋巴-血管间隙受累),PCNA状况,激素治疗,化疗周期和HER-2过表达与预后密切相关。 ALN转移,LVSI,PCNA状态和化疗周期是生存的独立预测因素。结论:HER-2过度表达的乳腺癌具有特殊的临床和病理学特征,具有晚期临床分期和较高的ER / PR双阴性率。淋巴结转移,LVSI,PCNA和化疗周期是预后的独立预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号